4N1K peptide

• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 英文名称: 4N1K peptide
• 英文别名: (2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]hexanoic acid
• 化学式: C₆₈H₁₀₅N₁₇O₁₂S
• 分子量: 1384.7
• InChiKey: XEMLJJZYMPZGBS-ITJFCMOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  98
• 可旋转键数：
  46
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  529
• 氢给体数：
  18
• 氢受体数：
  18

文献信息

• SYNTHETIC PEPTIDES INDUCING IMMUNOGENIC CELL DEATH
  申请人：SORBONNE UNIVERSITE

  公开号：EP3650036A1

  公开（公告）日：2020-05-13

  The invention relates to TSP-1-derived peptides capable of inducing immunogenic cell death, in particular immunogenic cancer cell death. It further relates to uses of such peptides, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof.

  本发明涉及能够诱导免疫性细胞死亡，特别是免疫性癌细胞死亡的 TSP-1 衍生肽。本发明还涉及此类肽的用途，特别是制备药物组合物，以允许或提高有需要的受试者治疗癌症的效率。
• Method and pharmaceutical composition for use in the treatment of cancer
  申请人：Susin Santos

  公开号：US10759843B2

  公开（公告）日：2020-09-01

  The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

  本发明涉及一种包含氨基酸序列的可溶性多肽：KRFYVVMWKK（SEQ ID NO:1）或其功能保守变体，用于治疗癌症。 本发明还涉及一种用于治疗癌症的药物组合物，该组合物包含至少一种根据本发明的可溶性肽或至少一种根据本发明的酸核酸或至少一种根据本发明的表达载体或至少一种根据本发明的宿主细胞和药学上可接受的载体。
• Method and Pharmaceutical Composition for use in the Treatment of Cancer
  申请人：INSERM (Institut National de la Sante et de la Recherche Medicale)

  公开号：US20150126456A1

  公开（公告）日：2015-05-07

  The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
• Method and Pharmaceutical Composition for Use in the Treatment of Cancer
  申请人：INSERM ( Institut National de la Sante et de la Recherche Medicale)

  公开号：US20170362302A1

  公开（公告）日：2017-12-21

  The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
• METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER
  申请人：Susin Santos

  公开号：US20190135898A1

  公开（公告）日：2019-05-09

  The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.